Experimental combo therapy shows promise in advanced cancers, but trial halted early
NCT ID NCT04916002
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less information than hoped. The main goal was to see how many patients' tumors responded and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vidutolimod (CMP-001) and cemiplimab (Libtayo)
What this could lead to
If successful, this combination could offer a new treatment option for several advanced cancers by boosting the immune system to attack tumors.
What could go wrong
The trial was terminated early, so results are limited. It is unclear if the combination is effective or safe; side effects from immune activation can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dartmouth Clinical Trial Office
Lebanon, New Hampshire, 03756, United States
-
East Carolina University
Greenville, North Carolina, 27858, United States
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
GenesisCare USA
Jacksonville, Florida, 32204, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oncology Consultants
Houston, Texas, 77030, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Peter MacCallum Cancer Centre (PMCC) and The Royal Melbourne Hospital
Melbourne, Victoria, 3050, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
St. Vincent's Hospital
Darlinghurst, New South Wales, 2010, Australia
-
UC San Diego Moores Cancer Center
La Jolla, California, 92037-0845, United States
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of California
Los Angeles, California, 90095, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Utah Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
University of Washington
Seattle, Washington, 98109, United States
-
VA Maryland Health Care System
Baltimore, Maryland, 20814, United States